AR020107A1 - METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS - Google Patents
METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTSInfo
- Publication number
- AR020107A1 AR020107A1 ARP990103295A ARP990103295A AR020107A1 AR 020107 A1 AR020107 A1 AR 020107A1 AR P990103295 A ARP990103295 A AR P990103295A AR P990103295 A ARP990103295 A AR P990103295A AR 020107 A1 AR020107 A1 AR 020107A1
- Authority
- AR
- Argentina
- Prior art keywords
- activity
- fusion protein
- full length
- cell
- presenilin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Método para identificar una sustancia capaz de reducir o eliminar la actividad de la presenilinasa, que comprende las etapas: a)se cultiva una célula olínea celular que expresa dicha actividad de presenilinasa y un proteína de fusion, comprendiendo dicha proteína de fusion la presenilina 1 o presenilina 2 delongitud completa y un reportero, b)dicha célula o línea celular se incuba con un compuesto de ensayo, c)empleando el reportero,se mide la cantidad de proteínade fusion de longitud completa d)la cantidad de proteína de fusion de longitud completa medida se compara con la cantidad de proteína de fusion de longitudcompleta medida para un testigo. La sustancias identificables por un método como el descripto más arriba, que son capaces de reducir o de eliminar laactividad de la presenilinasa. Una composicion farmacéutica que comprende una sustancia como la definida más arriba y un vehículo aceptable farmacéuticamentepara la misma. El uso de una sustancia como la indicada más arriba en la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas ode la enfermedad de Alzheimer o Alzheimer familia. Hasta el momento solo existían tratamientos sintomáticos de las enfermedades neurodegenerativas y, enparticular, de la enfermedad de Alzheimer. No habia ningun tratamiento modificador de la enfermedad que hiciera frente a la patología de dichas enfermedades.Tampoco existía forma terapéutica alguna para prevenir la patología debida a la deposicion de amiloidey la subsiguiente formacion de placas de amiloide.Tampoco existía forma terapéutica alguna de prevenir la muerte celular neuronal debida a fragmentos de presenilina normales o alternativos que pueden serproducir la apoptosis.Se descubrio que la supresion de la generacion de dichos fragmentos de presenilina, que pueden ser la forma biologicamente activa de laspresenilinas, y subsiguientemente el impedimento de la deposicion de amiloide,pueden realizarse reduciendo o eliminando la actividad de lapresenilinasa.Frente a estos inconvenientes del estado de la técnica, el invento propone métodos para identificar sustancias altamente específicas que son capaces deMethod for identifying a substance capable of reducing or eliminating the activity of presenilinase, which comprises the steps: a) a cell-olympic cell expressing said presenilinase activity and a fusion protein, said fusion protein comprising presenilin 1 or Presenilin 2 full length and a reporter, b) said cell or cell line is incubated with a test compound, c) using the reporter, the amount of full length fusion protein is measured d) the amount of full length fusion protein measurement is compared with the amount of full length fusion protein measured for a control. The substances identifiable by a method like the one described above, which are capable of reducing or eliminating the activity of presenilinase. A pharmaceutical composition comprising a substance as defined above and a pharmaceutically acceptable carrier for it. The use of a substance such as that indicated above in the preparation of a drug for the treatment of neurodegenerative diseases or of the Alzheimer's disease or Alzheimer's family. So far there were only symptomatic treatments of neurodegenerative diseases and, in particular, of Alzheimer's disease. There was no disease-modifying treatment to cope with the pathology of these diseases. There was also no therapeutic way to prevent the pathology due to the deposition of amyloid and the subsequent formation of amyloid plaques. There was also no therapeutic way to prevent death. neuronal cell due to normal or alternative presenilin fragments that may be producing apoptosis. It was discovered that the suppression of the generation of said presenilin fragments, which may be the biologically active form of laspresenilines, and subsequently the impediment of amyloid deposition, they can be carried out by reducing or eliminating the activity of lapresenilinase. In the face of these drawbacks of the prior art, the invention proposes methods for identifying highly specific substances that are capable of
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98112688 | 1998-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020107A1 true AR020107A1 (en) | 2002-04-10 |
Family
ID=8232244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990103295A Pending AR020107A1 (en) | 1998-07-09 | 1999-07-07 | METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1095279A1 (en) |
| JP (1) | JP2002520031A (en) |
| AR (1) | AR020107A1 (en) |
| AU (1) | AU5034099A (en) |
| CA (1) | CA2332344A1 (en) |
| UY (1) | UY25604A1 (en) |
| WO (1) | WO2000003248A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10000161A1 (en) * | 2000-01-06 | 2001-07-19 | Boehringer Ingelheim Pharma | Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard |
| EP1305634A2 (en) * | 2000-04-03 | 2003-05-02 | Bristol-Myers Squibb Company | Fluorescence assay for gamma-secretase activity and inhibitors |
| JP2021525245A (en) * | 2018-05-22 | 2021-09-24 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Gene therapy for Alzheimer's disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0876483A1 (en) * | 1996-01-26 | 1998-11-11 | HSC Research and Development Limited Partnership | Nucleic acids and proteins related to alzheimer's disease, and uses therefor |
| GB9608657D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel treatment |
| CA2288227A1 (en) * | 1997-04-24 | 1998-10-29 | The General Hospital Corporation | A purified 20 kda presenilin 2 c-terminal fragment and methods of screening for compounds that inhibit proteolysis of presenilin 2 |
-
1999
- 1999-07-07 AR ARP990103295A patent/AR020107A1/en active Pending
- 1999-07-08 WO PCT/EP1999/004805 patent/WO2000003248A1/en not_active Application Discontinuation
- 1999-07-08 EP EP99934634A patent/EP1095279A1/en not_active Withdrawn
- 1999-07-08 CA CA002332344A patent/CA2332344A1/en not_active Abandoned
- 1999-07-08 AU AU50340/99A patent/AU5034099A/en not_active Abandoned
- 1999-07-08 JP JP2000559432A patent/JP2002520031A/en active Pending
- 1999-07-09 UY UY25604A patent/UY25604A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY25604A1 (en) | 2000-02-23 |
| AU5034099A (en) | 2000-02-01 |
| WO2000003248A1 (en) | 2000-01-20 |
| EP1095279A1 (en) | 2001-05-02 |
| CA2332344A1 (en) | 2000-01-20 |
| JP2002520031A (en) | 2002-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yamamoto et al. | Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation | |
| Bevelander et al. | The effect of the administration of tetracycline on the development of teeth | |
| Dong et al. | Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease | |
| KR102436886B1 (en) | Neurodegenerative disorders | |
| BRPI0408256A (en) | compound, methods of treating a human or animal by limiting cell replication, suffering from cancer, suffering from a neoplastic disease, and suffering from proliferative diseases, use of a compound, and process for the preparation of a compound or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof | |
| MXPA02012164A (en) | Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. | |
| Shigyo et al. | Extracellular vimentin is a novel axonal growth facilitator for functional recovery in spinal cord-injured mice | |
| DE60126980D1 (en) | THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES | |
| Wang et al. | A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation | |
| BRPI0409427A (en) | compound, use thereof, pharmaceutical composition, method of treating a human suffering from a hyperproliferative disease, and process for the preparation of a compound or a pharmaceutically acceptable salt, ester or prodrug thereof | |
| JP2022511785A (en) | Compositions and Methods for Treating Dementia | |
| CZ300549B6 (en) | Pharmaceutical composition containing cilobradine | |
| JPH03145419A (en) | Drug of preventing ultraviolet light aging | |
| EP1707202A1 (en) | Organic compounds | |
| Pan et al. | Novel Caspase-1 inhibitor CZL80 improves neurological function in mice after progressive ischemic stroke within a long therapeutic time-window | |
| AR020107A1 (en) | METHOD FOR IDENTIFYING A CAPABLE SUBSTANCE TO REDUCE OR ELIMINATE THE ACTIVITY OF PRESENYLINASE, SUBSTANCES IDENTIFIABLE WITH THIS METHOD, YOU ARE LAST IN THE DEVELOPMENT OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PHARMACEUTIOTIVE COMPONENTS | |
| KR101173677B1 (en) | Pharmaceutical composition for preventing or treating diseases associated with beta amyloid accumulation containing EPPS as an active ingredient | |
| JP4800194B2 (en) | Use of kahalalide compounds for the manufacture of a treatment for psoriasis | |
| DE112018005145T5 (en) | INHIBITION OF AMINOACYLASE 3 (AA3) IN TREATMENT OF CANCER | |
| KR20220076375A (en) | A novel pharmaceutical composition for treating neurodegenerative disease | |
| WO2023047810A1 (en) | Regulator for primary cilia of immune-related cells and use thereof | |
| CN104292126B (en) | Naphthalene derivatives and the application on medicine thereof | |
| AR005724A1 (en) | BIOLOGICALLY ACTIVE UREID DERIVATIVES USEFUL IN THE TREATMENT OF MULTIPLE SCLEROSIS | |
| ITUB20159141A1 (en) | TREATMENT OF CEREBRAL TUMOR | |
| Zubachyk et al. | Biopharmaceutical evaluation of new semi-solid preparation with thiotriazoline and chloramphenicol |